BRIEF published on 03/31/2026 at 13:12, 1 month 9 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
BRIEF published on 03/31/2026 at 13:12, 1 month 9 days ago Poxel cède le PXL770 à Scynexis pour une valeur potentielle de 196 millions de dollars Accord Financier Poxel PXL770 SCYNEXIS Polykystose Rénale
BRIEF published on 03/31/2026 at 13:12, 1 month 9 days ago Poxel vend le PXL770 à Scynexis pour un montant pouvant atteindre 196 millions de dollars Biopharmaceutique Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 1 month 9 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
PRESS RELEASE published on 03/31/2026 at 13:07, 1 month 9 days ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) Poxel annonce la cession du PXL770 à Scynexis pour jusqu'à 196 millions de dollars, renforçant sa position financière. Étude clinique phase 2 prévue pour ADPKD. Accord financier détaillé Cession Accord Financier Poxel PXL770 SCYNEXIS
PRESS RELEASE published on 03/31/2026 at 13:07, 1 month 9 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Poxel announces sale of PXL770 for up to $196 million to SCYNEXIS. PXL770 targets ADPKD. Agreement includes upfront payment, development and commercial milestones. Phase 2 study planned for Q4 2026 Milestones Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/25/2026 at 22:03, 1 month 15 days ago Poxel Secures Additional Financing Through New Tranche D PDR Bonds Financing Continuation Plan Poxel IPF Partners Tranche D PDR
BRIEF published on 03/25/2026 at 22:03, 1 month 15 days ago Poxel obtient un financement supplémentaire grâce à de nouvelles obligations PDR de tranche D Financement Poxel Tranche D PDR Partenaires De L'IPF Plan De Continuité
PRESS RELEASE published on 03/25/2026 at 21:58, 1 month 15 days ago Inside Information / News release on accounts, results Poxel confirms drawdown under Tranche D PDR bond issue for €3.75 million with IPF as part of continuation plan validated by Lyon Commercial Court. Key details and financing prospects outlined Financing Opportunities Poxel IPF Partners Tranche D PDR
PRESS RELEASE published on 03/25/2026 at 21:58, 1 month 15 days ago Informations privilégiées / Communiqué sur comptes, résultats Poxel confirme la mise à disposition de l’emprunt obligataire complémentaire Tranche D PDR dans le cadre du plan de continuation. Analyse des termes de la Tranche D PDR et sécurisation du financement Financement Emprunt Obligataire Plan De Continuation Poxel Tranche D PDR
Published on 05/09/2026 at 01:30, 1 day 10 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 12 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 11:45, 38 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 17 hours 18 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 15 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 17 hours ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 17 hours ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days 17 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 17 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 17 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 17 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 17 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
